Ontology highlight
ABSTRACT:
SUBMITTER: Lilenbaum RA
PROVIDER: S-EPMC10175038 | biostudies-literature | 2016 May
REPOSITORIES: biostudies-literature
Lilenbaum Rogerio A RA Horn Leora A LA
Journal of the National Comprehensive Cancer Network : JNCCN 20160501 5 Suppl
For appropriate treatment selection, the updated NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) recommend broad molecular profiling for all patients with nonsquamous disease. Three different tyrosine kinase inhibitors (TKIs) are recommended as first-line treatment of EGFR mutation-positive NSCLC: gefitinib, erlotinib, and afatinib. Most patients whose disease responds will still experience progression, and the type of disease progression drives management. Systemic progression requires s ...[more]